Related Experiment Video
Updated: Jul 5, 2026
10:21
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
Targeting Ras in myeloid leukemias.
Benjamin S Braun1, Kevin Shannon
1Department of Pediatrics, University of California, San Francisco, CA 94143, USA. braunb@peds.ucsf.edu <braunb@peds.ucsf.edu>
Summary
Ras proteins are crucial for cell signaling and are frequently mutated in cancers. This review explores strategies to target these mutations, particularly in myeloid malignancies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Ras proteins are key signal transducers activated by cell surface receptors.
- Oncogenic mutations in Ras genes occur in ~30% of human cancers.
- Activating KRAS and NRAS mutations are prevalent in pancreatic, lung, colon cancers, and myeloid leukemia.
Purpose of the Study:
- To review general strategies for targeting hyperactive Ras signaling in cancer.
- To focus on the application of these strategies in myeloid malignancies.
Main Methods:
- Literature review of Ras signaling pathways.
- Analysis of oncogenic mutations in KRAS and NRAS.
- Discussion of therapeutic approaches targeting Ras.
Main Results:
- Ras signaling is a critical pathway in cancer development.
- Specific Ras mutations drive various cancer types, including myeloid leukemia.
- Targeting Ras offers a promising therapeutic avenue.
Conclusions:
- Hyperactive Ras signaling presents a viable target for cancer therapy.
- Developing strategies to inhibit Ras is essential for treating cancers with Ras mutations.
- Further research into Ras-targeted therapies, especially for myeloid malignancies, is warranted.
Related Concept Videos
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
01:24Small GTPases - Ras and Rho
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...